Last year, MassBio’s Annual Meeting was rebranded to the “State of Possible Conference” to celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. We had amazing speakers take the stage to address everything from drug pricing and patient access to venture funding and opioid addition, and we honored Boston Fire Commissioner Joseph Finn with the first-ever State of Possible Award at a post-event celebration at the Museum of Science. As we gear up for our 2020 State of Possible Conference, scheduled for March 25-26, we wanted to take a moment to reflect on the highlights of 2019:
|
MassBio President & CEO, Robert K. Coughlin, welcomes attendees to the State of Possible Celebration at the Museum of Science. |
Lita Nelson, Retired Director of the MIT Technology Licensing Office, shares her insights on the growth, evolution, and “magic sauce” of Kendall Square. |
|
Lauren Bombardier Weeks, Patient Advocate, delivers an inspiring Possible Talk on her experience as a Cystic Fibrosis patient. |
Katrine Bosley, former CEO of Editas Medicine, and John Maraganore, CEO of Alnylam, talk RNAi and CRISPR with Mike Nikitas, the event MC. |
|
Jeremy Levin, Chairman & CEO of Ovid Therapeutics, delivers the morning keynote on the history of biotech and what lays ahead. |
Boston Fire Commissioner Joseph Finn accepts the first-ever 2019 State of Possible Award at the Museum of Science. |
|
Tamar Thompson, previously the Executive Director, State Government Affairs & Federal Payment at Bristol-Myers Squibb, talks about solving the value equation to ensure patient access. |
Panelists discuss Massachusetts’ role in Digital Health, drawing insights from MassBio’s report on the state of digital health in the Commonwealth and what we need to do to become a leading digital health cluster. |
Join us for the 2020 State of Possible Conference! Early bird pricing & registration opens at 8 am on Monday, January 6th. To learn more, visit the event page.